May 23, 2017 / 10:41 AM / 4 months ago

BRIEF-Prometic presents new data on PBI-4050 and plasminogen

May 23 (Reuters) - Prometic Life Sciences Inc:

* Prometic presents new data on PBI-4050 and plasminogen at American Thoracic Society’s 2017 international conference

* Prometic Life Sciences Inc - PBI-4050 + nintedanib provided a statistically significant benefit over pbi-4050 + pirfenidone

* Prometic Life Sciences - intends to initiate a second phase 2/3 placebo-controlled trial in which IPF patients who failed to tolerate either nintedanib or pirfenidone

* Prometic Life Sciences Inc - Prometic plans to initiate both studies in second half of 2017. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below